Mattson Financial Services LLC Purchases 7,257 Shares of DexCom, Inc. $DXCM

Key Points

• Mattson Financial Services LLC increased its holdings in DexCom, Inc. by 34.4%, now owning 28,376 shares valued at approximately $1.94 million after purchasing 7,257 shares in the first quarter.
• DexCom's latest quarterly earnings report showed $0.48 earnings per share, beating estimates, and a 15.2% year-over-year revenue growth totaling $1.16 billion.
• Institutional investors own 97.75% of DexCom's stock, highlighting significant interest from the investment community.

Mattson Financial Services LLC lifted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 34.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,376 shares of the medical device company's stock after purchasing an additional 7,257 shares during the quarter. Mattson Financial Services LLC's holdings in DexCom were worth $1,938,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Horizon Investments LLC increased its holdings in shares of DexCom by 2.2% in the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after purchasing an additional 123 shares during the period. Nia Impact Advisors LLC increased its holdings in shares of DexCom by 1.4% in the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after purchasing an additional 140 shares during the period. Wedbush Securities Inc. increased its holdings in shares of DexCom by 1.2% in the first quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after purchasing an additional 157 shares during the period. Argonautica Private Wealth Management Inc. increased its holdings in shares of DexCom by 3.2% in the first quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after purchasing an additional 182 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. increased its holdings in shares of DexCom by 3.2% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company's stock worth $411,000 after purchasing an additional 187 shares during the period. Institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

NASDAQ DXCM opened at $76.00 on Thursday. The company has a 50-day simple moving average of $81.14 and a two-hundred day simple moving average of $78.90. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The firm has a market cap of $29.80 billion, a price-to-earnings ratio of 52.78, a PEG ratio of 1.64 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the business posted $0.43 earnings per share. The company's revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on DXCM. Wall Street Zen cut DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Raymond James Financial increased their target price on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. UBS Group increased their target price on DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. William Blair raised DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Finally, Mizuho increased their target price on DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

Insider Buying and Selling

In related news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the transaction, the director directly owned 51,121 shares of the company's stock, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kyle Malady sold 667 shares of DexCom stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares in the company, valued at approximately $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 17,855 shares of company stock valued at $1,477,344 over the last quarter. Company insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.